PubMed Health⌕ Search

Biomedical subjects

A U Bertland

Publications and source records attributed to A U Bertland.

10 recordsLinked to original sources
PubMed1976

Vaccine against human hepatitis B.

A highly purified and inactivated vaccine was made of hepatitis B virus surface antigen. The vaccine was tested exhaustively for safety by ordinary procedures and additionally in chimpanzees and marmosets. It was highly potent and induced antibody in guinea pigs, grivet monkeys, and chimpanzees after three doses of vaccine were given subcutaneously. Chimpanzees given three doses of vaccine were protected against challenge with 1,000 chimpanzee-infectious doses of live human hepatitis B virus given intravenously in controlled studies. Tests of the vaccine for control of hepatitis B in man are to be carried out.

Animals↗
PubMed1976

Development and chimpanzee testing of a vaccine against human hepatitis B.

Highly purified hepatitis B virus surface antigen (Australia antigen) purified by physical and chemical procedures from infected human plasma was used to prepare hepatitis B vaccine. The purified antigen was treated with formalin and the vaccine was tested exhaustively for safety by ordinary procedures and additionally in marmosets (for live hepatitis B virus). The vaccine was highly potent, inducing antibody in guinea pigs, grivet monkeys, and chimpanzees given three doses of vaccine containing up to 20 mug of hepatitis B antigen per dose. A protective efficacy trial was carried out in chimpanzees that were given three doses of vaccine subcutaneously and then challenged intravenously with 1000 chimpanzee infectious doses of human hepatitis B virus. All of five unvaccinated control animals developed hepatitis B virus antigenemia following challenge and all of six vaccinated animals were protected, including one animal that had failed to develop detectable antibody following vaccination.

Animals↗
PubMed1970

The reductive inactivation of UDPgalactose-4-epimerase from yeast and E. coli.

The prosthetic groups of UDPgalactose-4-epimerase from yeast and E. coli can be reduced by incubation with D-galactose or L-arabinose provided that 5' uridylic acid (5'UMP) is also present. This type of concerted reduction can also be performed using sodium borohydride. The latter type of reduction also depends on the addition of 5'UMP. Enzymatic analysis of the released prosthetic group by means of lactic dehydrogenase and pyruvate revealed that the pyridine nucleotide of the reduced epimerase generated in the concerted reaction is dehydrogenated in the 4-position of the pyridine ring. The catalytic activity of the reduced epimerase is much lower than that of epimerase (10-15% of native epimerase). This reductive inactivation was also found in crude epimerase preparations from E. coli, again provided 5'UMP is present. Fractionated E. coli epimerase subjected to the concerted reduction show a striking fluorescent enhancement of the order of magnitude of that observed in the purified yeast epimerase. Unlike the latter, however, E. coli epimerase also becomes fluorescent upon addition of the specific substrate UDPgalactose. The physiological aspects of the phenomenon as related to induction of the galactose genes is discussed.

Arabinose↗
PubMedDate not supplied

Purified and inactivated human hepatitis B vaccine: progress report.

Developments leading to the preparation and testing for safety and potency of a highly purified inactivated preparation of hepatitis B surface antigen are descirbed. Protective efficacy studies in chimps of a lot of the inactivated hepatitis B vaccine are currently and suitable for clinical trials in man.

Animals↗